These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22128301)

  • 1. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
    Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
    Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
    Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
    Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    Wu X; Li Q; Zhang F; Wang L; Wang J; Fan J; Di G; Guo C
    Food Chem Toxicol; 2021 Jan; 147():111892. PubMed ID: 33271260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.